AbbVie unimpressed as Galapagos' hopes of catching Vertex narrow further

2 July 2018

AbbVie (NYSE: ABBV) has ended its interest in collaborating further with the Dutch biotech company Galapagos (Euronext: GLPG) on one of its cystic fibrosis (CF) regimens.

The US drugmaker has decided not to proceed with the second triple combination that the companies had been working on, comprising of the potentiator GLPG3067, C1 corrector GLPG2222, and C2 corrector GLPG2737.

This decision is based on Phase II trial data on GLPG2737 in adult CF patients who are homozygous for the Class II F508del mutation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK